Market Overview The U.S. anorexiants market emphasizes oral generics for accessibility, with a surge in branded injectables like GLP-1 agonists for severe cases. Dominated by obesity applications, it benefits from FDA approvals and telehealth integration, though regulatory scrutiny on long-term use persists. The market's growth mirrors CDC data showing severe obesity rising to 9.7%...